BIOA vs LNTH vs NUVL vs RMD vs KYMR

For growth investors, ResMed Inc.

(RMD) is the stronger pick with 9. 8% revenue growth year-over-year, versus -16. 7% for Kymera Therapeutics, Inc. (KYMR). ResMed Inc. (RMD) offers the better valuation at 21. 8x trailing P/E (18. 8x forward), making it the more compelling value choice. Analysts rate BioAge Labs, Inc. (BIOA) a "Buy" — based on 3 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, ResMed Inc.

(RMD) is the cheapest at 21. 8x versus Lantheus Holdings, Inc. at 26. 7x. On forward P/E, Lantheus Holdings, Inc. is actually cheaper at 17. 5x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Nuvalent, Inc.

(NUVL) delivered a total return of +446. 1%, compared to -2. 7% for BioAge Labs, Inc. (BIOA). Over 10 years, the gap is even starker: LNTH returned +41. 9% versus BIOA's -2. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Lantheus Holdings, Inc.

(LNTH) is the lower-risk stock at 0. 47β versus BioAge Labs, Inc. 's 1. 41β — meaning BIOA is approximately 200% more volatile than LNTH relative to the S&P 500. On balance sheet safety, Lantheus Holdings, Inc. (LNTH) carries a lower debt/equity ratio of 0% versus 14% for ResMed Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), ResMed Inc.

(RMD) is pulling ahead at 9. 8% versus -16. 7% for Kymera Therapeutics, Inc. (KYMR). On earnings-per-share growth, the picture is similar: BioAge Labs, Inc. grew EPS 66. 2% year-over-year, compared to -48. 9% for Nuvalent, Inc.. Over a 3-year CAGR, LNTH leads at 18. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

ResMed Inc.

(RMD) is the more profitable company, earning 27. 2% net margin versus -896. 1% for BioAge Labs, Inc. — meaning it keeps 27. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: RMD leads at 32. 7% versus -1031. 5% for BIOA. At the gross margin level — before operating expenses — BIOA leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Lantheus Holdings, Inc.

(LNTH) trades at 17. 5x forward P/E versus 18. 8x for ResMed Inc. — 1. 3x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for BIOA: 152. 5% to $45. 00.

In this comparison, RMD (1.

0% yield) pays a dividend. BIOA, LNTH, NUVL, KYMR do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, ResMed Inc.

(RMD) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 66), 1. 0% yield, +293. 8% 10Y return). Both have compounded well over 10 years (RMD: +293. 8%, BIOA: -2. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

RMD pays a dividend while BIOA, LNTH, NUVL, KYMR do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.